<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixteen patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) and 15 patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) associated with subcortical white matter lesions or subcortical cardiovascular accidents (<z:chebi fb="4" ids="46274">CVAs</z:chebi>) were treated with <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> for 16 weeks </plain></SENT>
<SENT sid="1" pm="."><plain>Within-group analyses for the AD group revealed significant improvement on some tests of working memory, and marginal improvement on the Mini-Mental State Examination and on tests of immediate free recall from a serial list-learning task </plain></SENT>
<SENT sid="2" pm="."><plain>Identical analyses for the VaD group revealed substantial gains on tests of working memory and delayed recognition memory </plain></SENT>
<SENT sid="3" pm="."><plain>These data suggest that medication such as <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> may act to improve the working <z:e sem="disease" ids="C0233794" disease_type="Mental or Behavioral Dysfunction" abbrv="">memory deficits</z:e> known to be associated with <z:hpo ids='HP_0000726'>dementia</z:hpo> patients with subcortical vascular lesions </plain></SENT>
<SENT sid="4" pm="."><plain>The clinical implications of these findings are discussed </plain></SENT>
</text></document>